XML 172 R128.htm IDEA: XBRL DOCUMENT v3.22.4
Financial assets and liabilities measured at fair value - Summary of Assets and Liabilities Measured at Fair Value (Details) - EUR (€)
€ in Millions
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Unquoted debt securities not meeting the definition of equity instruments      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value € 115 € 78 € 63
Level 1      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 10,765 6,449 10,022
Total financial liabilities measured at fair value 0 0 0
Level 1 | Bayer contingent purchase consideration arising from the acquisition of Genzyme      
Disclosure of information on income statement [line items]      
Total financial liabilities measured at fair value 0 0 0
Level 1 | MSD contingent consideration (European vaccines business)      
Disclosure of information on income statement [line items]      
Total financial liabilities measured at fair value 0 0 0
Level 1 | Shire contingent consideration arising from the acquisition of Translate Bio      
Disclosure of information on income statement [line items]      
Total financial liabilities measured at fair value 0 0 0
Level 1 | Contingent consideration arising from acquisition of Amunix      
Disclosure of information on income statement [line items]      
Total financial liabilities measured at fair value 0 0 0
Level 1 | Other contingent consideration arising from business combinations and acquisitions      
Disclosure of information on income statement [line items]      
Total financial liabilities measured at fair value 0 0 0
Level 1 | Non-current derivatives      
Disclosure of information on income statement [line items]      
Total financial liabilities measured at fair value 0 0 0
Level 1 | Current derivatives      
Disclosure of information on income statement [line items]      
Total financial liabilities measured at fair value 0 0 0
Level 1 | Quoted equity investments      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 387 396 439
Level 1 | Unquoted equity investments      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 0 0 0
Level 1 | Quoted debt securities      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 329 447 426
Level 1 | Unquoted debt securities not meeting the definition of equity instruments      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 0 0 0
Level 1 | Contingent consideration relating to divestments      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 0 0 0
Level 1 | Financial assets held to meet obligations under deferred compensation plans      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 512 549 454
Level 1 | Non-current derivatives      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 0 0 0
Level 1 | Current derivatives      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 0 0 0
Level 1 | Mutual fund investments      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 9,537 5,057 8,703
Level 2      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 206 298 82
Total financial liabilities measured at fair value 326 85 297
Level 2 | Bayer contingent purchase consideration arising from the acquisition of Genzyme      
Disclosure of information on income statement [line items]      
Total financial liabilities measured at fair value 0 0 0
Level 2 | MSD contingent consideration (European vaccines business)      
Disclosure of information on income statement [line items]      
Total financial liabilities measured at fair value 0 0 0
Level 2 | Shire contingent consideration arising from the acquisition of Translate Bio      
Disclosure of information on income statement [line items]      
Total financial liabilities measured at fair value 0 0 0
Level 2 | Contingent consideration arising from acquisition of Amunix      
Disclosure of information on income statement [line items]      
Total financial liabilities measured at fair value 0 0 0
Level 2 | Other contingent consideration arising from business combinations and acquisitions      
Disclosure of information on income statement [line items]      
Total financial liabilities measured at fair value 0 0 0
Level 2 | Non-current derivatives      
Disclosure of information on income statement [line items]      
Total financial liabilities measured at fair value 232 6 92
Level 2 | Current derivatives      
Disclosure of information on income statement [line items]      
Total financial liabilities measured at fair value 94 79 205
Level 2 | Quoted equity investments      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 0 0 0
Level 2 | Unquoted equity investments      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 0 0 0
Level 2 | Quoted debt securities      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 0 0 0
Level 2 | Unquoted debt securities not meeting the definition of equity instruments      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 0 0 0
Level 2 | Contingent consideration relating to divestments      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 0 0 0
Level 2 | Financial assets held to meet obligations under deferred compensation plans      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 0 0 0
Level 2 | Non-current derivatives      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 0 3 24
Level 2 | Current derivatives      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 206 295 58
Level 2 | Mutual fund investments      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 0 0 0
Level 3      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 967 883 695
Total financial liabilities measured at fair value 779 714 605
Level 3 | Bayer contingent purchase consideration arising from the acquisition of Genzyme      
Disclosure of information on income statement [line items]      
Total financial liabilities measured at fair value 26 59 104
Level 3 | MSD contingent consideration (European vaccines business)      
Disclosure of information on income statement [line items]      
Total financial liabilities measured at fair value 204 269 312
Level 3 | Shire contingent consideration arising from the acquisition of Translate Bio      
Disclosure of information on income statement [line items]      
Total financial liabilities measured at fair value 380 354 0
Level 3 | Contingent consideration arising from acquisition of Amunix      
Disclosure of information on income statement [line items]      
Total financial liabilities measured at fair value 165 0 0
Level 3 | Other contingent consideration arising from business combinations and acquisitions      
Disclosure of information on income statement [line items]      
Total financial liabilities measured at fair value 4 32 189
Level 3 | Non-current derivatives      
Disclosure of information on income statement [line items]      
Total financial liabilities measured at fair value 0 0 0
Level 3 | Current derivatives      
Disclosure of information on income statement [line items]      
Total financial liabilities measured at fair value 0 0 0
Level 3 | Quoted equity investments      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 0 0 0
Level 3 | Unquoted equity investments      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 549 427 149
Level 3 | Quoted debt securities      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 0 0 0
Level 3 | Unquoted debt securities not meeting the definition of equity instruments      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 115 78 63
Level 3 | Contingent consideration relating to divestments      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 303 378 483
Level 3 | Financial assets held to meet obligations under deferred compensation plans      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 0 0 0
Level 3 | Non-current derivatives      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 0 0 0
Level 3 | Current derivatives      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 0 0 0
Level 3 | Mutual fund investments      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value € 0 € 0 € 0